An Exploratory, Uncontrolled, Open-labeled Trial to Evaluate the Effect of FMX-8 Treatment for Anemia in Patients With Chronic Kidney Disease (CKD), Stage 4 or 5
Phase of Trial: Phase 0
Latest Information Update: 05 Jun 2015
Price : $35 *
At a glance
- Drugs FMX 8 (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors FerruMax Pharmaceuticals
- 02 Jun 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 24 Nov 2014 According to the ClinicalTrials.gov record, status changed from not yet recruiting to recruiting.
- 04 Sep 2014 New trial record